Crux of the updated terms:

1) Risk-benefit and cost-benefit analyses of existing and newly FDA-authorized mRNA andother COVID-19 immunizations, and immunization schedules as it relates to COVID-19immunization to inform use recommendations, personalized per age-group, major risk factorsand health status.

2) To identify critical gaps in the existing scientific and clinical knowledge and methodologiesrelated to the safety and efficacy of the COVID-19 immunizations, to inform thedevelopment of policy recommendations and further analyses and research by the CDC,other related federal agencies, and the scientific community

3) To review and summarize data, clinical and scientific knowledge related to adverse eventsassociated with COVID-19 immunizations to inform immunization recommendations interms of precautions and contraindications to receipt of immunization